In the present study, we aimed to assess the levels and changes over time of pNfH and NfL in the CSF of type 3 SMA patients treated with intrathecal Nusinersen, to explore their use as a potential biomarkers of treatment response. Here, NEFL is linked to spinal muscular atrophy, type III.